Paper Details

  1. Home
  2. Paper Details

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial.

Author: ChopadaManojkumar B, CutlerMark W, GruberWilliam C, JuergensChristine, Le Dren-NarayaninNatacha, Schmoele-ThomaBeate, ScottDaniel A, SolankiBhagirath B, SundaraiyerVani, SupePravin

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study in India evaluated the safety and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged 50 to 65 years. The vaccine was well tolerated and elicited robust immune responses against all 13 pneumococcal serotypes.
Paper Details　
Original Abstract of the Article :
Streptococcus pneumoniae infection is a major global public health concern in older adults, especially as life expectancy continues to increase in most countries, including India. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) with the ability to enhance immunity (immunologic memory) o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612423/

データ提供：米国国立医学図書館（NLM）

Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine in Adults

This research explores the safety and effectiveness of a 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged 50 to 65 years in India. The researchers conducted an open-label trial, investigating the vaccine's ability to elicit robust immune responses and its safety profile in this population group.

PCV13's Efficacy and Safety

The researchers found that PCV13 induced robust immune responses against all 13 pneumococcal serotypes. This was reflected in a significant increase in functional antibody levels after vaccination. Importantly, no serious adverse events were reported. These findings provide valuable insights into the safety and immunogenicity of PCV13 in adults, indicating its potential to protect against pneumococcal disease.

A Promising Vaccine for Adults

The study underscores the importance of vaccinating adults, especially those in the age group of 50 to 65 years. It's like a camel caravan equipping itself with supplies for a long journey – preparedness is key for a successful and safe trek. The findings highlight the potential of PCV13 to protect adults against pneumococcal disease, contributing to a healthier and more resilient population.

Dr. Camel's Conclusion

This study demonstrates the safety and effectiveness of PCV13 in adults, emphasizing the importance of vaccination for a healthier population. It's like a camel caravan navigating a vast desert – a well-prepared caravan is more likely to overcome challenges and reach its destination safely.

Date :
  1. Date Completed 2018-05-14
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

28881165

DOI: Digital Object Identifier

PMC5612423

Related Literature

Article Analysis
・Effects of pneumococcal polysaccharide vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.